Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Boris Guiu
Bifractionated CPT-11 With LV5FU2 Infusion (FOLFIRI-3) in Combination With Bevacizumab: Clinical Outcomes in First-Line Metastatic Colorectal Cancers According to Plasma Angiopoietin-2 Levels
BMC Cancer
Cancer Research
Oncology
Genetics
Related publications
A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation
OncoTargets and Therapy
Oncology
Pharmacology
Impact of Tumour RAS/BRAF Status in a First-Line Study of Panitumumab + FOLFIRI in Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
FOLFIRI® and Bevacizumab in First-Line Treatment for Colorectal Cancer Patients: Safety, Efficacy and Genetic Polymorphisms
BMC Research Notes
Biochemistry
Medicine
Genetics
Molecular Biology
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
Angiopoietin-2 Levels Are Associated With Disease Progression in Metastatic Malignant Melanoma
Clinical Cancer Research
Cancer Research
Oncology
Discontinuation of First-Line Bevacizumab in Metastatic Colorectal Cancer: The BEAWARE Italian Observational Study
Tumori
Medicine
Cancer Research
Oncology
